Identification and Characterization of 4-[[4-(2-Butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S) -thiomorpholinecarboxamide (TMI-1), a Novel Dual Tumor Necrosis Factor-α-Converting Enzyme/Matrix Metalloprotease Inhibitor for the Treatment of Rheumatoid Arthritis

Journal of Pharmacology and Experimental Therapeutics

Volumn 309, Issue 1, 2004, Pages 348-355

  Zhang, Yuhua ^a   Xu, Jun ^b   Levin, Jeremy ^b   Hegen, Martin ^a   Li, Guangde ^a   Robertshaw, Heidi ^d   Brennan, Fionula ^d   Cummons, Terri ^b   Clarke, Dave ^b   Vansell, Nichole ^b   Nickerson Nutter, Cheryl ^a   Barone, Dauphine ^c   Mohler, Ken ^c   Black, Roy ^c   Skotnicki, Jerry ^b   Gibbons, Jay ^b   Feldmann, Marc ^d   Frost, Philip ^b   Larsen, Glenn ^a   Lin, Lih Ling ^a  

^a PFIZER INC   (United States)

^b WYETH RESEARCH   (United States)

^c AMGEN INC   (United States)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [[4 (2 BUTYNYLOXY)PHENYL]SULFONYL] N HYDROXY 2,2, DIMETHYLTHIOMORPHOLINECARBOXAMIDE; COLLAGEN; CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MATRIX METALLOPROTEINASE INHIBITOR; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; BLOOD; COLLAGEN INDUCED ARTHRITIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG MECHANISM; ENZYME BINDING; ENZYME INHIBITION; EXPLANT; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; INHIBITION KINETICS; MEMBRANE BINDING; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; RHEUMATOID ARTHRITIS; RIBONUCLEASE PROTECTION ASSAY; STRUCTURE ACTIVITY RELATION; SYNOVIUM; VALIDATION PROCESS;

ADAM PROTEINS; ANIMALS; ARTHRITIS, RHEUMATOID; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; HUMANS; LIPOPOLYSACCHARIDES; MATRIX METALLOPROTEINASES; METALLOENDOPEPTIDASES; MICE; MICE, INBRED DBA; MORPHOLINES; RNA, MESSENGER; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 12144287462     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.059675     Document Type: Article

References (40)

1. Akassoglou K, Probert L, Kontogeorgos G, and Kollias G (1997) Astrocyte-specific but not neuron-specific transmembrane TNF triggers inflammation and degeneration in the central nervous system of transgenic mice. J Immunol 158:438-445.
2. Beck G, Bottomley G, Bradshaw D, Brewster M, Broadhurst M, Devos R, Hill C, Johnson W, Kim H, Kirtland S, et al. (2002) (E)-2(R)-[1(S)-(Hydroxycarbamoyl)-4-phenyl-3-butenyl]-2′-isobutyl-2′ -(methanesulfonyl)-4-methylvalerohydrazide (Ro 32-7315), a selective and orally active inhibitor of tumor necrosis factor-alpha convertase. J Pharmacol Exp Ther 302:390-396.
3. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, et al. (1997) A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature (Lond) 385:729-733.
4. Butler DM, Maini RN, Feldmann M, and Brennan FM (1995) Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur Cytokine Netw 6:225-230.
5. Chabaud M, Garnero P, Dayer JM, Guerne PA, Fossiez F, and Miossec P (2000) Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. Cytokine 12:1092-1099.
6. Choy EH and Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907-916.
7. Constantinescu CS, Grygar C, Kappos L, and Leppert D (2001) Interleukin 15 stimulates production of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by human peripheral blood mononuclear cells. Cytokine 13:244-247.
8. Conway JG, Andrews RC, Beaudet B, Bickett DM, Boncek V, Brodie TA, Clark RI, Crumrine RC, Leenitzer MA, Mcdougald DL, et al. (2001) Inhibition of tumor necrosis factor-a production and arthritis in the rat by GW3333, a dual inhibitor of TNF-a-converting enzyme and matrix metalloproteinases. J Pharmacol Exp Ther 298:900-908.
9. Crowe PD, Walter BN, Mohler KM, Otten-Evans C, Black RA, and Ware CF (1995) A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes. J Exp Med 181:1205-1210.
10. Decker T, Lohmann-Matthes ML, and Gifford GE (1987) Cell-associated tumor necrosis factor (TNF) as a killing mechanism of activated cytotoxic macrophages. J Immunol 138:957-962.
11. Decoster E, Vanhaesebroeck B, Boone E, Plaisance S, De Vos K, Haegeman G, Grooten J, and Fiers W (1998) Induction of unresponsiveness to tumor necrosis factor (TNF) after autocrine TNF expression requires TNF membrane retention. J Biol Chem 273:3271-3277.
12. Dekkers PE, Lauw FN, ten Hove T, te Velde AA, Lumley P, Becherer D, van Deventer SJ, and van der Poll T (1999) The effect of a metalloproteinase inhibitor (GI5402) on tumor necrosis factor-alpha (TNF-alpha) and TNF-alpha receptors during human endotoxemia. Blood 94:2252-2258.
13. Drummond AH, Beckett P, Brown PD, Bone EA, Davidson AH, Galloway WA, Gearing AJ, Huxley P, Laber D, McCourt M, et al. (1999) Preclinical and clinical studies of MMP inhibitors in cancer. Ann NY Acad Sci 878:228-235.
14. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, and Bijl Hea (1994a) Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105-1110.
15. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, and Woody JN (1994b) Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 344:1125-1127.
16. Feldmann M, Brennan FM, Elliott M, Katsikis P, and Maini RN (1994) TNF alpha as a therapeutic target in rheumatoid arthritis. Circ Shock 43:179-184.
17. Feldmann M, Brennan FM, Foxwell BM, and Maini RN (2001) The role of TNF alpha and IL-1 in rheumatoid arthritis. Curr Dir Autoimmun 3:188-199.
18. Feldmann M, Charles P, Taylor P, and Maini RN (1998) Biological insights from clinical trials with anti-TNF therapy. Springer Semin Immunopathol 20:211-228.
19. Fernandes JC, Martel-Pelletier J, and Pelletier JP (2002) The role of cytokines in osteoarthritis pathophysiology. Biorheology 39:237-246.
20. Gracie JA, Forsey RJ, Chan WL, Gilmour A, Leung BP, Greer MR, Kennedy K, Carter R, Wei XQ, Xu D, et al. (1999) A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Investig 104:1393-1401.
21. Jin G, Huang X, Black R, Wolfson M, Rauch C, McGregor H, Ellestad G, and Cowling R (2002) A continuous fluorimetric assay for tumor necrosis factor-alpha converting enzyme. Anal Biochem 302:269-275.
22. Katrib A, Tak PP, Bertouch JV, Cuello C, McNeil HP, Smeets TJ, Kraan MC, and Youssef PP (2001) Expression of chemokines and matrix metalloproteinases in early rheumatoid arthritis. Rheumatology (Oxford) 40:988-994.
23. Knight C, Willenbrock F, and Murphy G (1992) A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett 296:263-266.
24. Kobayashi H, Ohshima S, Nishioka K, Yamaguchi N, Umeshita-Sasai M, Ishii T, Mima T, Kishimoto T, Kawase I, and Saeki Y (2002) Antigen induced arthritis (AIA) can be transferred by bone marrow transplantation: evidence that interleukin 6 is essential for induction of AIA. J Rheumatol 29:1176-1182.
25. Kriegler M, Perez C, DeFay K, Albert I, and Lu SD (1988) A novel form of TNF/ cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 53:45-53.
26. Maskos K, Fernandez-Catalan C, Huber R, Bourenkov GP, Bartunik H, Ellestad GA, Reddy P, Wolfson MF, Rauch CT, Castner BJ, et al. (1998) Crystal structure of the catalytic domain of human tumor necrosis factor-alpha-converting enzyme. Proc Natl Acad Sci USA 95:3408-3412.
27. McInnes IB and Liew FY (1998) Interleukin 15: a proinflammatory role in rheumatoid arthritis synovitis. Immunol Today 19:75-79.
28. Mohler KM, Sleath PR, Fitzner JN, Cerretti DP, Alderson M, Kerwar SS, Torrance DS, Otten-Evans C, Greenstreet T, Weerawarna K, et al. (1994) Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature (Lond) 370:218-220.
29. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, et al. (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337:141-147.
30. Moss ML, White JM, Lambert MH, and Andrews RC (2001) TACE and other ADAM proteases as targets for drug discovery. Drug Discov Today 6:417-426.
31. Mueller C, Corazza N, Trachsel-Loseth S, Eugster HP, Buhler-Jungo M, Brunner T, and Imboden MA (1999) Noncleavable transmembrane mouse tumor necrosis factor-alpha (TNFalpha) mediates effects distinct from those of wild-type TNFalpha in vitro and in vivo. J Biol Chem 274:38112-38118.
32. Newton RC, Solomon KA, Covington MB, Decicco CP, Haley PJ, Friedman SM, and Vaddi K (2001) Biology of TACE inhibition. Ann Rheum Dis 60:25-32.
33. Ohta S, Harigai M, Tanaka M, Kawaguchi Y, Sugiura T, Takagi K, Fukasawa C, Hara M, and Kamatani N (2001) Tumor necrosis factor-alpha (TNF-alpha) converting enzyme contributes to production of TNF-alpha in synovial tissues from patients with rheumatoid arthritis. J Rheumatol 28:1756-1763.
34. Pap T, Shigeyama Y, Kuchen S, Fernihough JK, Simmen B, Gay RE, Billingham M, and Gay S (2000) Differential expression pattern of membrane-type matrix metalloproteinases in rheumatoid arthritis. Arthritis Rheum 43:1226-1232.
35. Rudek MA, Venitz J, and Figg WD (2002) Matrix metalloproteinase inhibitors: do they have a place in anticancer therapy? Pharmacotherapy 22:705-720.
36. Ruuls SR, Hoek RM, Ngo VN, McNeil T, Lucian LA, Janatpour MJ, Korner H, Scheerens H, Hessel EM, Cyster JG, et al. (2001) Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation. Immunity 15:533-543.
37. Shaw T, Nixon JS, and Bottomley KM (2000) Metalloproteinase inhibitors: new opportunities for the treatment of rheumatoid arthritis and osteoarthritis. Expert Opin Investig Drugs 9:1469-1478.
38. Solomon KA, Covington MB, DeCicco CP, and Newton RC (1997) The fate of proTNF-alpha following inhibition of metalloprotease-dependent processing to soluble TNF-alpha in human monocytes. J Immunol 159:4524-4531.
39. Tomita T, Nakase T, Kaneko M, Shi K, Takahi K, Ochi T, and Yoshikawa H (2002) Expression of extracellular matrix metalloproteinase inducer and enhancement of the production of matrix metalloproteinases in rheumatoid arthritis. Arthritis Rheum 46:373-378.
40. Ziolkowska M, Koc A, Luszczykiewicz G, Ksiezopolska-Pietrzak K, Klimczak E, Chwalinska-Sadowska H, and Maslinski W (2000) High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol 164:2832-2838.